RAFT-AF Trial

Jason Gencher presented the RAFT-AF Trial which was a randomized, multicenter, open-label trial comparing ablation-based rhythm control to rate control among patients with high-burden paroxysmal (>4 episodes in 6 months) or persistent (duration <3 years) AFib, NYHA II to III HF, and elevated NT-proBNP. The primary outcome was a composite of all-cause mortality and all HF events, with a minimum follow-up of 2 years. The trial was published in Circulation this past June and presented at ACC in 2021.